Study of suboptimum treatment response: Lessons from breast cancer

Lancet Oncology

Volumn 4, Issue 3, 2003, Pages 177-185

  Lönning, Per Eystein ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; HORMONE; PACLITAXEL;

BREAST CANCER; CANCER PATIENT; CAUSE OF DEATH; CLINICAL STUDY; DNA MICROARRAY; DRUG EFFECT; DRUG RESPONSE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; IN VIVO STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SIDE EFFECT;

EID: 0037338906     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01022-2     Document Type: Review

References (85)

1. Clarke M, Collins R, Davies C, et al. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.
2. Abe O, Abe R, Enomoto K, et al. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-42.
3. McGuire WL. Steroid receptors in human breast cancer. Cancer Res 1978; 38: 4289-91.
4. Degenshein GA, Bloom N, Tobin E. The value of progesterone receptor assays in the management of advanced breast cancer. Cancer 1980; 46: 2789-93.
5. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000; 89: 111-17.
6. Therrase P, Arbuck SG, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst 2000; 92: 205-16.
7. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-66.
8. DiLeo A, Larsimont D, Gancberg D, et al. HER-2 and topoisomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001; 12: 1081-89.
9. Skipper H, Perry S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res 1970; 30: 1883-97.
10. Shackney S, McCormack G, Cuchural G. Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Intern Med 1978; 89: 107-21.
11. NOrton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61: 1307-17.
12. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998; 90: 1205-11.
13. Fisher B, Andersohn S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858-69.
14. Bastit P, Chevallier B, Chevreau C, et al. Epirubicin-based chemotheraphy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000; 18: 3115-24.
15. Bergh J, Wiklund T, Erikstein B, et al. Tailored flourouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet 2000; 356: 1384-91.
16. Stadtmauer EA, ONeill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069-76.
17. Thor AD, Berry DA, Budman Dr, et al.ERBB-2,p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: 1346-60.
18. Paik SM, Bryant J, Park CH, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-70.
19. Frizelle SP, Grim J, Zhou J, et al. Re-expression of p16 INK4a in mesothelioma cells results in cell cycle arrest cell death tumor suppression and tumor regression. Oncogene 1998; 16: 3087-95.
20. Kataoka M, Wiehle S, Spitz F, et al. Down-regulation of BCL-2 is associated with p16(INK4)-mediated apoptosis in non-small cell lung cancer cells. Oncogene 2000; 19: 1589-95.
21. Ries SJ, Brandts CH, Chung AS, et al. Loss of p14(ARF) in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 2000; 6: 1128-33.
22. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
23. Miller KD, McCaskillStevens W, Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17: 3033-37.
24. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomised trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413-24.
25. Ando M, Watanabe T, Nagata K, et al. Efficacy of docetaxel 60 mg/m(2) in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 2001; 19: 336-42.
26. Rustgi AK. Translational research: what is it? Gastroenterology 1999; 116: 1285.
27. Friedman HS, Bigner SH, Bigner DD. Cyclosphosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). J Neurooncol 1995; 24: 103-08.
28. Bartelink H. From translational research to improved local control and survival. Int J Radiat Oncol 2001; 49: 311-18.
29. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998; 52: 261-88.
30. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
31. Hähnel R, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer 1979; 44: 671-75.
32. Vollenweider-Zerargui L, Barrelet L, Wong Y, et al. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women: clinical correlation on 547 patients. Cancer 1986; 57: 1171-80.
33. McGuire WL. Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. J Clin Oncol 1988; 6: 1071-72.
34. Kamby C, Rasmussen BR, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases: relation to pattern of spread and survival after recurrence. Br J Cancer 1989; 60: 252-57.
35. Clark GM, Sledge GW, Osborne Ck, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1987; 5: 55-61.
36. Battaglia F, Scambia G, Rossi S, et al. Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement. Eur J Cancer Clin Oncol 1988; 24: 1685-90.
37. Howat JMT, Barnes DM, Harris M, Swindell R. The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer 1983; 47: 629-40.
38. Silvestrini R, Daidone MG, DiFronzo G. Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 1979; 44: 665-70.
39. Singh L, Wilson AJ, Baum M, et al. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Novaldex') trial. Br J Cancer 1988; 57: 612-14.
40. Moriki T, Takahashi T, Hiroi M, et al. Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU: an immunohistochemical study including correlations with p53, c-erbB-2 and estrogen receptor status. Pathol Int 1996; 46: 417-25.
41. Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001; 19: 314-21.
42. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-606.
43. Kaufmann M, Bajetta E, Dirix LY, et al. Examestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000; 18: 1399-11.
44. Gebhardt F, Zanker KS, Brandt B. Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micrometastases from breast cancer patients. Biochem Biophys Res Commun 1998; 247: 319-23.
45. Geisler S, Ln̈ning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505-12.
46. Bates S, Vousden KH. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 1999; 55: 28-37.
47. Hayward JL, Rubens RD, Carbone PP, et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292-98.
48. Dowsett M, Detre S, Ormerod MG, et al. Analysis and sorting of apoptotic cells from fine-needle aspirates of exercised human primary breast carcinomas. Cytometry 1998; 32: 291-300.
49. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-52.
50. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
51. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50-56.
52. Makris A, Powles TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997; 3: 593-600.
53. Formenti SC, Dunnington G, Uzieli B, et al. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys 1997; 39: 1059-68.
54. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 2: 72-79.
55. Steger GG, Wenzel C, Schmidiger MP, et al. HER2-status predicts complete pathological response (pCR) in primary operable breast cancer (BC) treated with neoadjuvant epirubicin/docetaxel plus G-CSF. Breast Cancer Res Treat 2000; 64: abstr 23, 31.
56. Giannakakou P, Sackett DL, Ward Y, et al. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2000; 2: 709-17.
57. Sledge Jr GW, Neuberg D, Ingle J, et al. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol 1997; 16: 1a, 2 (abstr).
58. Joensuu H, Holli K, Heikkinen M, et al.Combination chemotherapy versus single-agent therapy as first and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998; 16: 3720-30.
59. Bastholt L, Dalmark M, Gjedde SB, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996; 14: 1146-55.
60. Brandt L, Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in indolent non-Hodgkins lymphoma. Acta Oncol 2001; 40: 213-23.
61. McClay EF, McClay MET. Systemic chemotherapy for the tratment of metastatic melanoma. Semin Oncol 1996; 23: 744-53.
62. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-69.
63. Khayat D, Antoine EC, Nizri D, et al. Neoadjuvant chemotherapy in breast cancer: simple prognostic, or useful predictive factor? In: Perry MC (Ed) The education book of the 37th meeting of the American Society of Clinical Oncology (ASCO). Alexandria, VA: ASCO, 2001: 510-15.
64. Ueda Y, Hijikata M, Takagi S, et al. Transcriptional activities of p73 splicing variants are regulated by inter-variant association. Biochem J 2001; 356; 859-66.
65. Sigalas I, Calvert AH, Anderson JJ, et al. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996; 2: 912-17.
66. Lizard-Nacol S, Coudert B, Riedinger JM, et al. p53 gene alterations are associated with a decreased responsiveness to neoadjuvant chemotherapy in human breast cancer. Int J Oncol 1997; 10: 1203-07.
67. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001; 1: 233-40.
68. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast cancer. Cancer Res 2001; 61: 5345-48.
69. Järvinen TAH, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II alpha associate with ERBB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156: 839-47.
70. Kannan K, Amariglio N, Rechavi G, et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001; 20: 2225-34.
71. Wen WH, Bernstein L, Lescallett J, et al. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 2000; 60: 2716-22.
72. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector apaf-1 in malignant melanoma. Nature 2001; 409: 207-11.
73. Sr̈lie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
74. van't Veer L, Dal H, van de Vijver M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-36.
75. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-26.
76. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415: 436-42.
77. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
78. Yeoh E, Ross M, Shurtleff S, et al. Classification subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-43.
79. Beer D, Kardia S, Huang C-C, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816-24.
80. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406: 536-40.
81. van't Veer LJ, De Jong D. The microarray way to tailored cancer treatment. Nat Med 2002; 8: 13-14.
82. Wang E, Miller LD, Ohnmacht GA, et al. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000; 18: 457-59.
83. Wittliff JL, Kunitake ST, Chu SS, Travis JC. Applications of laser capture microdissection in genomics and proteomics. J Clin Ligand Assay 2000; 23: 66-73.
84. Voss T, Ahorn H, Harbel P, et al. Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int J Cancer 2001; 91: 180-86.
85. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science 1997; 276: 1268-72.